FDA Approved: PAZOPANIB — Supplemental Application (Apotex Corp.)

View source ↗

Summary

FDA approved a supplemental application for pazopanib by Apotex Corp. (ANDA 217713), likely involving labeling or other post-approval changes for the generic pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma
• Soft Tissue Sarcoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

SUPPL AP for PAZOPANIB (PAZOPANIB)